Trial
NCT01343823
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Shire
Collaborators
—
Condition
ACE Inhibitor Induced Angioedema
Intervention
ecallantide 60 mg
Why stopped
Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-11